Clinical trial shows promising results in a two-drug combination that curbs methamphetamine use

A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment, UCLA-led research suggests. Participants in the ADAPT-2 clinical trial who received a combination of injectable naltrexone plus extended-release oral bupropion (NTX+BUPN) had a 27% increase in methamphetamine-negative urine tests, indicating reduced usage. By contrast, the placebo group had an 11% increase in negative tests. The study is published in the journal Addiction. “These findings have important implications for pharmacological treatment for methamphetamine use Read More

Related posts:

  1. Clinical trial reports promising new treatment reduces suffering in Sanfilippo syndrome
  2. New protein drug trial produces promising safety results for rare pulmonary condition
  3. Cholesterol-lowering drug slows progression of eye disease in people with diabetes: Clinical trial
  4. Successful trial for new colorectal cancer treatment highlights promising immunotherapy drugs
  5. AI model to improve clinical trial recruitment for eye disease
  6. Clinical trial investigates using electronic alerts to help control blood pressure
  7. Breakthrough brain recording device receives FDA approval for a clinical trial
  8. First-of-its-kind clinical trial eliminates or shrinks melanoma tumors in 70% of patients

Leave a Reply

Your email address will not be published. Required fields are marked *